A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias von Cortes, J.E, Kim, D.-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F.E, Apperley, J.F, Khoury, H.J, Talpaz, M, DiPersio, J, DeAngelo, D.J, Abruzzese, E, Rea, D, Baccarani, M, Müller, M.C, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, V.M, Clackson, T, Turner, C.D, Haluska, F.G, Guilhot, F, Deininger, M.W, Hochhaus, A, Hughes, T, Goldman, J.M, Shah, N.P, Kantarjian, H

Volltext

19 AN OBJECTIVE GENETIC ONTOGENY CLASSIFICATION IDENTIFIES TRUE BIOLOGICAL SECONDARY AML AMONG DE NOVO AML PATIENTS ≥60 YEARS OLD von Lindsley, R.C, Mar, B.G, Mazzola, E, Grauman, P.G, Lindeman, N, Steensma, D.P, DeAngelo, D.J, Wadleigh, M, Neuberg, D, Stone, R.M, Ebert, B.L

Volltext

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia von Stone, R M, Fischer, T, Paquette, R, Schiller, G, Schiffer, C A, Ehninger, G, Cortes, J, Kantarjian, H M, DeAngelo, D J, Huntsman-Labed, A, Dutreix, C, del Corral, A, Giles, F

Volltext

Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia von DeAngelo, D J, Stevenson, K E, Dahlberg, S E, Silverman, L B, Couban, S, Supko, J G, Amrein, P C, Ballen, K K, Seftel, M D, Turner, A R, Leber, B, Howson-Jan, K, Kelly, K, Cohen, S, Matthews, J H, Savoie, L, Wadleigh, M, Sirulnik, L A, Galinsky, I, Neuberg, D S, Sallan, S E, Stone, R M

Volltext

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies von DeAngelo, D J, Spencer, A, Bhalla, K N, Prince, H M, Fischer, T, Kindler, T, Giles, F J, Scott, J W, Parker, K, Liu, A, Woo, M, Atadja, P, Mishra, K K, Ottmann, O G

Volltext

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia von Akahane, K, Sanda, T, Mansour, M R, Radimerski, T, DeAngelo, D J, Weinstock, D M, Look, A T

Volltext

SYK regulates mTOR signaling in AML von Carnevale, J, Ross, L, Puissant, A, Banerji, V, Stone, R M, DeAngelo, D J, Ross, K N, Stegmaier, K

Volltext

Quantitative assessment of inotuzumab ozogamicin (InO) response relative to investigator’s choice of chemotherapy (ICC) in adults with relapsed or refractory (R/R) CD22+ B-Cell acu... von Ruiz-Garcia, A., Vandendries, E., DeAngelo, D.J., Kantarjian, H.M., Boni, J.

Volltext

Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities von Alloo, A., Sheu, J., Butrynski, J.E., DeAngelo, D.J., George, S., Murphy, G.F., LeBoeuf, N.R.

Volltext

The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy von Wang, L D, Rao, T N, Rowe, R G, Nguyen, P T, Sullivan, J L, Pearson, D S, Doulatov, S, Wu, L, Lindsley, R C, Zhu, H, DeAngelo, D J, Daley, G Q, Wagers, A J

Volltext

PRO143 PSYCHOMETRIC EVALUATION OF THE ADVANCED SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ADVSM-SAF) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS von Taylor, F., Shields, A., Li, S., Yip, C., Padilla, B., Green, T., Radia, D., Deininger, M., Gotlib, J.R., Bose, P., Drummond, M.W., Hexner, E., Robinson, W., Quiery, A., Winton, E.F., DeAngelo, D.J., Mar, B.

Volltext

PS954 TIME FROM RANDOMIZATION TO FIRST SUBSEQUENT INDUCTION/SALVAGE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN IN... von Jabbour, E., Stelljes, M., Advani, A., DeAngelo, D.J., Wang, T., Neuhof, A., Vandendries, E., Kantarjian, H.

Volltext

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia von Feldman, E J, Cortes, J, DeAngelo, D J, Holyoake, T, Simonsson, B, O'Brien, S G, Reiffers, J, Turner, A R, Roboz, G J, Lipton, J H, Maloisel, F, Colombat, P, Martinelli, G, Nielsen, J L, Petersdorf, S, Guilhot, F, Barker, J, Kirschmeier, P, Frank, E, Statkevich, P, Zhu, Y, Loechner, S, List, A

Volltext

PS951 MORE OR LESS? IMPACT OF DOSE NUMBER ON OUTCOMES OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN von Marks, D.I., DeAngelo, D.J., Jabbour, E., Advani, A., O’Brien, S., Wang, T., Neuhof, A., Vandendries, E., Kantarjian, H., Stock, W., Stelljes, M., Cassaday, R.

Volltext

PS949 INOTUZUMAB OZOGAMICIN (INO) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): OUTCOMES OF PATIENTS TREATED IN SALVAGE ONE WITH A LONG DUR... von Stelljes, M., Jabbour, E., Advani, A., DeAngelo, D.J., Marks, D.I., Stock, W., O’Brien, S., Cassaday, R.D., Wang, T., Neuhof, A., Vandendries, E., Kantarjian, H.

Volltext

PS950 EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED IN THE INO‐VATE TRIAL: OUTCOMES BY SALVAGE‐TREAT... von Jabbour, E., Stelljes, M., Advani, A.S., DeAngelo, D.J., Gökbuget, N., Marks, D.I., Stock, W., O’Brien, S., Cassaday, R.D., Wang, T., Neuhof, A., Vandendries, E., Kantarjian, H.

Volltext

S830 AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) von Radia, D., Deininger, M.W., Gotlib, J., Bose, P., Drummond, M.W., Hexner, E.O., Robinson, W.A., Quiery, A.T., Winton, E., George, T.I., Horny, H.‐P., Oren, R., Shi, H., Schmidt‐Kittler, O., Mar, B., DeAngelo, D.J.

Volltext

S884 COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY von Mauro, M.J., Kim, D.‐W., Cortes, J., Réa, D., Hughes, T.P., Minami, H., Breccia, M., DeAngelo, D.J., Talpaz, M., Hochhaus, A., Goh, Y.T., Le Coutre, P.D., Sondhi, M., Mishra, K., Hourcade‐Potelleret, F., Vanasse, G., Aimone, P., Lang, F.

Volltext